ID

34147

Description

A Combined GWAS and miRNA for the Identification of Bevacizumab Response Predictors in Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01598285

Lien

https://clinicaltrials.gov/show/NCT01598285

Mots-clés

  1. 14/01/2019 14/01/2019 -
Détendeur de droits

GSK group of companies

Téléchargé le

14 janvier 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Breast Cancer Invasive Nos NCT01598285

Eligibility Breast Cancer Invasive Nos NCT01598285

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with breast cancer, at a disseminated stage
Description

ID.1

Type de données

boolean

patients treated with bevacizumab in combination with weekly paclitaxel as first line chemotherapy and who have progressed
Description

ID.2

Type de données

boolean

alive patients authorizing the extraction and analysis of their biological samples.
Description

ID.3

Type de données

boolean

Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients with a second neoplasia
Description

ID.4

Type de données

boolean

deceased patients
Description

ID.5

Type de données

boolean

patients who have not agreed to participate in the study
Description

ID.6

Type de données

boolean

her2 positive patients
Description

ID.7

Type de données

boolean

patients with cns metastases when first treated with bevacizumab in combination with paclitaxel
Description

ID.8

Type de données

boolean

patients with local-regional recurrence only and
Description

ID.9

Type de données

boolean

patients with status ned (resected metastases)
Description

ID.10

Type de données

boolean

Similar models

Eligibility Breast Cancer Invasive Nos NCT01598285

Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
patients with breast cancer, at a disseminated stage
boolean
ID.2
Item
patients treated with bevacizumab in combination with weekly paclitaxel as first line chemotherapy and who have progressed
boolean
ID.3
Item
alive patients authorizing the extraction and analysis of their biological samples.
boolean
Item Group
C0680251 (UMLS CUI)
ID.4
Item
patients with a second neoplasia
boolean
ID.5
Item
deceased patients
boolean
ID.6
Item
patients who have not agreed to participate in the study
boolean
ID.7
Item
her2 positive patients
boolean
ID.8
Item
patients with cns metastases when first treated with bevacizumab in combination with paclitaxel
boolean
ID.9
Item
patients with local-regional recurrence only and
boolean
ID.10
Item
patients with status ned (resected metastases)
boolean

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial